Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...

An estimated 12,000 children are born with thalassemia major, a severe form of the disease, in India each year, accounting ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

VIJAYAWADA: Sickle cell anaemia and thalassemia remain major health concerns in the State, particularly among tribal ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Clinical trials for exa-cel have shown promising results that it has been authorised by the FDA and MHRA for use in beta thalassemia and sickle cell disease. These successes make CRISPR technology, as ...

Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the ...

LONDON, Jan 31 (Reuters) - Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that ... use in the NHS in August to treat beta thalassemia, another rare blood disorder.

The gene therapy will be available in specialist ... transfusion-dependent beta thalassemia. It is already being given to patients in other countries such as France, Germany and Italy.

Discover the latest addition to Children's Hospital Los Angeles' 10 cell and gene therapy treatments, including Casgevy for sickle cell disease ...